NICE
Guideline
Feb 2016
For professionals
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
therapeutic drug monitoring
drug level
anti-drug antibodies
ELISA
anti-TNF
NICE
Guideline
Jun 2023
For professionals
NICE's appraisal recommending upadacitinib (Rinvoq), a tablet, for adults with moderate to severe Crohn's disease after a biologic has not worked, stopped working or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Medicines
Biologics and newer medicines
Jargon explained
JAK inhibitor
small molecule
TNF-alpha inhibitor
NHS Lothian
Web page
Dec 2020
Patients and professionals
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
drug level
anti-drug antibodies
anti-TNF
shared care
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy
NICE
Guideline
Aug 2015
For professionals
NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
TNF-alpha inhibitor
patient access scheme
moderately to severely active
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Cochrane
Systematic review
Jul 2016
Patients and professionals
Mesalazine-type drugs (aminosalicylates) are widely used for ulcerative colitis, but this review found little evidence that they work for active Crohn's. Low and high doses of mesalazine were not clearly better than placebo. Some trials comparing high-dose mesalazine with budesonide gave mixed results.
Topics
Medicines
Jargon explained
aminosalicylate
5-ASA
mesalazine
New England Journal of Medicine
Study
May 2023
Patients and professionals
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics
Medicines
Immunosuppressants
Research
Jargon explained
JAK inhibitor
small molecule
induction
maintenance
herpes zoster
endoscopic response
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
Cochrane
Systematic review
Sep 2019
Patients and professionals
Compares the medicines used to stop Crohn's returning after an operation. The evidence was not strong enough to say which works best. Cases of pancreatitis and low white blood cell counts were seen with azathioprine-type drugs.
Topics
Surgery
Medicines
Jargon explained
network meta-analysis
endoscopic relapse
postoperative recurrence
NHS
Web page
Feb 2024
For patients
NHS advice on keeping the combined contraceptive pill working when you are sick or have diarrhoea. It explains when to take another pill and when to use extra protection such as condoms, including after diarrhoea lasting more than 24 hours.
Topics
Pregnancy and fertility
Toilet habits
Jargon explained
combined oral contraceptive pill
NICE
Guideline
Aug 2025
For professionals
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
conventional treatment